斯芬戈酶1调节和抑制的结构动力学
Baharak Abd Emami1, Ahmed Shubbar2, Hope Woods2
1Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA.
bioRxiv : the preprint server for biology
|November 24, 2025
概括
氨酸激酶1 (SK1) 调节涉及形状变化和酸化. 像PF-543这样的抑制剂通过诱导二元化阻断SK1,提供新的治疗策略.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 化学生物学 化学生物学
背景情况:
- 斯芬戈氨基激酶1 (SK1) 生产了斯芬戈氨基-1-酸盐,这是一种涉及癌症和其他疾病的脂质.
- 了解SK1的结构和动态对于开发向疗法至关重要,但仍然不太了解.
研究的目的:
- 阐明管理SK1调节和抑制的结构和动态机制.
- 调查酸化和抑制剂如何影响SK1的构造和活性.
主要方法:
- 综合光谱技术 (例如,NMR,FRET) 和计算建模 (例如,分子动力学模拟).
- 生物化学测试以评估酶活性和抑制剂结合.
- 位点定向的突变发生,以探测特定的残留功能.
主要成果:
- 酸化Ser225会引发形状变化,包括调节环的重新配置和盐桥的重组,促进膜结合和催化.
- 发现了一种新型的催化中间体,具有明显的形状和动态的脂质结合环1 (LBL-1).
- 像PF-543这样的强效抑制剂稳定非催化状态,并诱导LBL介导的二分化,防止膜协会和基质访问.
结论:
- SK1监管是一个由结构灵活性驱动的多层次过程.
- 针对SK1的抑制剂通过LBL-1诱导二分化,建立了一个新的抑制机制.
- 这些发现为设计下一代SK1向治疗癌症和其他疾病的治疗提供了框架.
相关概念视频
The JAK-STAT Signaling Pathway
11.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.8K
Amplifying Signals via Enzymatic Cascade
17.0K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
17.0K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Protein Kinases and Phosphatases
14.9K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
14.9K
Protein Kinases and Phosphatases
4.3K
4.3K
Allosteric Regulation
62.8K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
62.8K


